Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 740

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC

Open access
Planchard, David, Jänne, Pasi A., Cheng, Ying, Yang, James C.-H., Yanagitani, Noriko, Kim, Sang-We, Sugawara, Shunichi, Yu, Yan, Fan, Yun, Geater, Sarayut L., Laktionov, Konstantin, Lee, Chee K., Valdiviezo, Natalia, Ahmed, Samreen, Maurel, Jean-Marc, Andrasina, Igor, Goldman, Jonathan, Ghiorghiu, Dana, Rukazenkov, Yuri, Todd, Alex, Kobayashi, Kunihiko·2023·New England Journal of Medicine

Abstract

Background Osimertinib is a third-generation epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI–sensitizing and EGFR T790M resistance mutations. Evidence suggests that the addition of chemotherapy may extend the benefits of EGFR-TKI therapy. Methods In this phase 3, international, open-label trial, we randomly assigned in a 1:1 ratio patients with EGFR -mutated (exon 19 deletion or L858R mutation) advanced non–small-cell lung cancer (NSCLC) who had not previously received treatment for advanced disease to receive osimertinib (80 mg once daily) with chemotherapy (pemetrexed [500 mg per square meter of body-surface area] plus either cisplatin [75 mg per square meter] or carboplatin [pharmacologically guided dose]) or to receive osimertinib monotherapy (80 mg once daily). The primary end point was investigator-assessed progression-free survival. Response and safety were also assessed. Research Summary Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC Results A total of 557 patients underwent randomization. Investigator-assessed progression-free survival was significantly longer in the osimertinib–chemotherapy group than in the osimertinib group (hazard ratio for disease progression or death, 0.62; 95% confidence interval [CI], 0.49 to 0.79; P<0.001). At 24 months, 57% (95% CI, 50 to 63) of the patients in the osimertinib–chemotherapy group and 41% (95% CI, 35 to 47) of those in the osimertinib group were alive and progression-free. Progression-free survival as assessed according to blinded independent central review was consistent with the primary analysis (hazard ratio, 0.62; 95% CI, 0.48 to 0.80). An objective (complete or partial) response was observed in 83% of the patients in the osimertinib–chemotherapy group and in 76% of those in the osimertinib group; the median response duration was 24.0 months (95% CI, 20.9 to 27.8) and 15.3 months (95% CI, 12.7 to 19.4), respectively. The incidence of grade 3 or higher adverse events from any cause was higher with the combination than with monotherapy — a finding driven by known chemotherapy-related adverse events. The safety profile of osimertinib plus pemetrexed and a platinum-based agent was consistent with the established profiles of the individual agents. Conclusions First-line treatment with osimertinib–chemotherapy led to significantly longer progression-free survival than osimertinib monotherapy among patients with EGFR -mutated advanced NSCLC. (Funded by AstraZeneca; FLAURA2 ClinicalTrials.gov number, NCT04035486 .)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2306434

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 740

Metadata

Authors
Planchard, D., Jänne, P. A., Cheng, Y., Yang, J. C.-H., Yanagitani, N., Kim, S.-W., Sugawara, S., Yu, Y., Fan, Y., Geater, S. L., Laktionov, K., Lee, C. K., Valdiviezo, N., Ahmed, S., Maurel, J.-M., Andrasina, I., Goldman, J., Ghiorghiu, D., Rukazenkov, Y., Todd, A., & Kobayashi, K.
Venue
New England Journal of Medicine
Published
2023-11-23
Volume
389
Issue
21
Pages
1935-1948
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4388484248
Cited by
740
References
23
FWCI
117.39
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC. https://app.cochat.ai/papers/10.1056/nejmoa2306434
The paper
Planchard, D., Jänne, P. A., Cheng, Y., Yang, J. C.-H., Yanagitani, N., Kim, S.-W., Sugawara, S., Yu, Y., Fan, Y., Geater, S. L., Laktionov, K., Lee, C. K., Valdiviezo, N., Ahmed, S., Maurel, J.-M., Andrasina, I., Goldman, J., Ghiorghiu, D., Rukazenkov, Y., . . . Kobayashi, K. (2023). Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2306434

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.